Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NovaBridge Biosciences (NBP) Current Assets (2018 - 2025)

NovaBridge Biosciences (NBP) has 8 years of Current Assets data on record, last reported at $217.5 million in Q4 2025.

  • On a quarterly basis, Current Assets rose 23.11% to $217.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was $217.5 million, a 23.11% increase, with the full-year FY2025 number at $217.5 million, up 23.11% from a year prior.
  • Current Assets reached $217.5 million in Q4 2025 per NBP's latest filing, down from $232.8 million in the prior quarter.
  • Over the last five years, Current Assets for NBP hit a ceiling of $747.9 billion in Q4 2021 and a floor of $167.6 million in Q2 2025.
  • A 5-year average of $57.8 billion and a median of $232.8 million in 2025 define the central range for Current Assets.
  • Peak YoY movement for Current Assets: skyrocketed 92655.2% in 2021, then plummeted 99.93% in 2022.
  • Tracing NBP's Current Assets over 5 years: stood at $747.9 billion in 2021, then tumbled by 99.93% to $509.9 million in 2022, then tumbled by 36.35% to $324.5 million in 2023, then crashed by 45.55% to $176.7 million in 2024, then grew by 23.11% to $217.5 million in 2025.
  • Business Quant data shows Current Assets for NBP at $217.5 million in Q4 2025, $232.8 million in Q3 2025, and $167.6 million in Q2 2025.